EP. 1: Pathogenesis and Comorbidities of Plaque Psoriasis
Mark Lebwohl, MD, and Jerry Bagel, MD, MS, provide an overview of the pathogenesis of and comorbidities associated with plaque psoriasis.
EP. 2: Psychosocial Impact of Plaque Psoriasis
Linda F. Stein Gold, MD, delves into the psychosocial impacts of living with plaque psoriasis.
EP. 3: Assessing the Severity of Plaque: The Need for Topical vs Systemic Therapy
Leon Kircik, MD, and Jerry Bagel, MD, MS, explain their reasoning behind choosing whether a patient with plaque psoriasis is a candidate for either topical or systemic therapeutic agents.
EP. 4: Treatment Approaches to Plaque Psoriasis and the Importance of Topical Therapy
The panel addresses their treatment practices and procedure when first seeing a patient with plaque psoriasis, as well as the role of topical therapy in this disease.
EP. 5: Plaque Psoriasis and Phototherapy
Spearheaded by Dr Bagel, the panel explores the role of phototherapy in the treatment of plaque psoriasis.
EP. 6: Plaque Psoriasis: TNF-α and IL-12/23 Inhibitors
Mark Lebwohl, MD, and Jerry Bagel, MD, MS, review the currently available TNF-α and IL-12/23 inhibitors used to treat plaque psoriasis.
EP. 7: Plaque Psoriasis: IL-17 Inhibitors
Dr Kircik discusses the mechanisms of action involving IL-17 inhibitors when using them as a first-line therapy for plaque psoriasis.
EP. 8: Plaque Psoriasis: Contraindications of IL-23 Inhibitors
Dr Lebwohl explains the contraindications for IL-23 inhibitors when using them to treat plaque psoriasis.
EP. 9: Emerging Topical Therapy Options for Plaque Psoriasis
Drs Kircik and Stein Gold address roflumilast and tapinarof as new topical agents for the management of plaque psoriasis.
EP. 10: Introduction of a New Class of Agents: TYK2 Inhibitors
Dr Lebwohl provides insight on a new class of agents, the TYK2 inhibitors.
EP. 11: Plaque Psoriasis: POETYK PSO-1 and POETYK PSO-2 Trials
Jerry Bagel, MD, MS, provides and overview of the phase 3 POETYK PSO-1 and POETYK PSO-2 trials, while Leon Kircik, MD, reviews the efficacy and safety of each of them.
EP. 12: Plaque Psoriasis: BE READY Trial
Drs Bagel and Lebwohl discuss the new biologic agent, bimekuzumab, and the data results from the phase 3 BE READY trial.
EP. 13: Challenges in Plaque Psoriasis Treatment Therapy
The panel each list challenges and unmet needs faced when managing the treatment of plaque psoriasis.
EP. 14: Incorporating New Therapeutic Agents into Plaque Psoriasis Therapy
The panel ponders how they will incorporate the discussed new agents into their plaque psoriasis treatment processes.
EP. 15: Parting Wisdom on Plaque Psoriasis
Dr Lebwohl concludes by giving advice to community physicians and dermatologist on what they can do to improve treating patients with plaque psoriasis.
2 Clarke Drive Cranbury, NJ 08512